Eiger BioPharmaceuticals (EIGR) Misses Q3 EPS by 10c

Eiger BioPharmaceuticals (NASDAQ: EIGR) reported Q3 EPS of ($0.41), $0.10 worse than the analyst estimate of ($0.31). Revenue for the quarter came in at $3.2 million versus the consensus estimate of $4.91 million.

For earnings history and earnings-related data on Eiger BioPharmaceuticals (EIGR) click here.

You May Also Be Interested In

• Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics
• Ross Stores, Inc. (ROST) PT Raised to $240 at Bernstein SocGen Group
• CoStar Group acquires Zonda for $800M, adding new home data